ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Glaxo To File Experimental Diabetes Drug Albiglutide In Early 2013

By Sten Stovall LONDON--GlaxoSmithKline PLC (GSK) aims to file its experimental once-weekly diabetes drug albiglutide for regulatory approval early next year following the read-out from a series of clinical trials. The British company said Wednesday that top-line data from eight late-stage Phase III clinical studies had now been received and, when taken together, support advancing albiglutide to regulatory submission. Albiglutide is an investigational biological form of human GLP-1 and isn't currently approved anywhere in the world. Human Genome Sciences (HGSI) discovered albiglutide and licensed it to Glaxo for late-stage testing. The drug is a form of GLP-1--a human protein that helps the body maintain normal blood-sugar levels. Glaxo's regulatory filings for albiglutide will be based on a Phase III clinical development program comprising eight individual studies, known as Harmony 1 to Harmony 8, involving some 5,000 patients. The program is investigating the efficacy, tolerability and safety, including cardiovascular safety, of albiglutide as mono- and add-on therapy, in patients with Type 2 diabetes. The latest read out came from Harmony 8, a 52-week study comparing albiglutide with Januvia, made by Merck & Co (MRK). Glaxo said Harmony 8 "is the first completed study of a GLP-1 agonist to assess efficacy and safety across the spectrum of renal impairment from mild to severe, and the third of eight Harmony Phase III studies to complete." It said albiglutide was generally well-tolerated. Results from the eight studies rule out excess cardiovascular risk, according to a threshold prespecified by the U.S. Food and Drug Administration. "Analyses of the data support progression to submission and will be presented to health authorities in the coming months," the company said. Shares in Glaxo closed up 0.8% at 1,465 pence. -Write to Sten Stovall at Sten.Stovall@DowJones.com

Stock News for Merck (MRK)
DateTimeHeadline
04/20/201517:55:52U.S. Stocks Advance
04/20/201517:42:06U.S. Stock Futures Advance
04/20/201508:08:03Is Bristol-Myers Squibb. Co. About to Fall Apart?
04/20/201508:00:00TetraLogic and Merck to Collaborate on the Evaluation of Birinapant...
04/19/201517:47:22Merck Drug Shows Improved Odds for Melanoma Patients--update
04/19/201516:03:03Best Pure Play Investment in Cancer Drugs
04/19/201512:45:00Présentation au congrès annuel de l'AACR des résultats préliminaires de...
04/19/201512:45:00Early Findings with Pembrolizumab, Merck's Investigational Anti-PD-1...
04/19/201509:26:48Merck's Keytruda Shows Improved Survival Odds for Melanoma Patients
04/19/201508:30:00Présentation au congrès annuel de l'AACR et publication dans l...
04/19/201508:30:00Le pembrolizumab, le traitement anti-PD-1 expérimental de Merck...
04/19/201508:30:00Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with...
04/19/201508:30:00Pembrolizumab, Merck's Investigational anti PD-1 Therapy, Demonstrates...
04/18/201515:02:033 Drug Stocks Leading the Charge Against Infectious Diseases
04/18/201510:02:03What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
04/16/201508:03:02The Best Stock to Invest in Hep C
04/14/201513:30:00Phase III Trial of the Merck and NewLink Genetics Investigational...
04/14/201509:20:21Heat Biologics Is An Opportunity Among Soaring Immunotherapy...
04/14/201508:44:32The Growing Business Of Animal Healthcare
04/14/201507:00:00NewLink Genetics and Merck & Co Receives Vaccine Industry Excellence...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad